ASX:RNORhinomed Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Rhinomed Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.07 0.00 (0.00 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.07Now: A$0.07▼A$0.0750-Day RangeA$0.07MA: A$0.07▼A$0.0752-Week RangeA$0.06Now: A$0.07▼A$0.41Volume452,773 shsAverage Volume122,418 shsMarket Capitalization$12.35 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlines Rhinomed Limited, a medical technology company, researches, develops, and commercializes consumer and medical devices. The company identifies, acquires, and commercializes late stage therapeutic delivery technologies. It markets Turbine, a nasal dilator designed to assist to breathe easier during aerobic exercise; and Mute, a nasal dilator designed to enhance sleep quality by breathing more and snoring less. The company also develops Breathing Space Health that comprises of a range of wellness programs designed to help people get to sleep. In addition, it develops Sleep Apnea, a clinical trial solution to mild and moderate sleep apnea; creates drug delivery platform for delivering medication into the nose in an inhaled form or via a trans-dermal or trans-mucosal method; and researches and develops current programs focuses on olfactory pathway and wearable technology. The company sells its products through wholesalers, retail stores, and clinics, as well as online in the United States, Canada, the United Kingdom, Taiwan, Australia, and New Zealand. It serves clinicians and health care organizations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Cremorne, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Rhinomed. Previous Next 2.6 Community Rank Outperform VotesRhinomed has received 49 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRhinomed has received 45 “underperform” votes. (Add your “underperform” vote.)Community SentimentRhinomed has received 52.13% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Rhinomed and other stocks. Vote “Outperform” if you believe RNO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RNO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRhinomed does not currently pay a dividend.Dividend GrowthRhinomed does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rhinomed insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhinomed is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhinomed is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhinomed has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.52 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:RNO Previous Symbol CUSIPN/A CIKN/A Webwww.rhinomed.com.au Phone+61-3-84160900Debt Debt-to-Equity Ratio10.36 Current Ratio2.99 Quick Ratio2.58Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.67 million Price / Sales3.36 Cash FlowA$0.02 per share Price / Cash Flow3.48 Book ValueA$0.04 per share Price / Book1.97Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares169,206,000Market Cap$12.35 million Next Earnings DateN/A OptionableNot Optionable Receive RNO News and Ratings via Email Sign-up to receive the latest news and ratings for RNO and its competitors with MarketBeat's FREE daily newsletter. Rhinomed (ASX:RNO) Frequently Asked Questions How has Rhinomed's stock been impacted by COVID-19 (Coronavirus)? Rhinomed's stock was trading at A$0.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RNO shares have decreased by 33.6% and is now trading at A$0.07. View which stocks have been most impacted by Coronavirus. How were Rhinomed's earnings last quarter? Rhinomed Ltd (ASX:RNO) announced its earnings results on Thursday, February, 28th. The company reported ($0.02) EPS for the quarter. View Rhinomed's earnings history. Has Rhinomed been receiving favorable news coverage? News stories about RNO stock have trended negative this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Rhinomed earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Rhinomed. Who are some of Rhinomed's key competitors? Some companies that are related to Rhinomed include Equillium (EQ), Protalix Biotherapeutics (PLX), Memphasys (MEM), OptiBiotix Health (OPTI), ReNeuron Group (RENE), Zelda Therapeutics (ZLD), OKYO Pharma (OKYO), AmpliPhi Biosciences (ARMP), Botanix Pharmaceuticals (BOT), Race Oncology (RAC), Covalon Technologies (COV), Microbix Biosystems (MBX), Emerald Health Therapeutics (EMH), Ixico (IXI) and Oragenics (OGEN). View all competitors. Who are Rhinomed's key executives? Rhinomed's management team includes the following people: Mr. Michael Johnson, CEO, MD & DirectorMr. Sean Slattery, Chief Financial OfficerMr. Phillip Allen Hains, Company Sec. What is Rhinomed's stock symbol? Rhinomed trades on the ASX under the ticker symbol "RNO." What is Rhinomed's stock price today? One share of RNO stock can currently be purchased for approximately A$0.07. How big of a company is Rhinomed? Rhinomed has a market capitalization of $12.35 million and generates $3.67 million in revenue each year. What is Rhinomed's official website? The official website for Rhinomed is www.rhinomed.com.au. How can I contact Rhinomed? Rhinomed's mailing address is 97 Green St, RICHMOND, VIC 3121, Australia. The company can be reached via phone at +61-3-84160900. This page was last updated on 7/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
